Cyclacel Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Bio Green Med Solution

15/08/2024 05:28

* Cyclacel Pharmaceuticals Inc  CYCC.OQ  reported a
quarterly
adjusted loss of 72 cents​​ per share for the quarter ended in
June, higher than the same quarter last year, when the company
reported EPS of $-6.60.  The mean expectation of two analysts
for the quarter was for a loss of $1.43 per share. Wall Street
expected results to range from $-2.04 to -83 cents per share.
    * Revenue fell 98.9% to $4.00 thousand from a year ago;
analysts
expected $30.00 thousand. 
    * The company reported a quarterly loss of $3.26 million.
    * Cyclacel Pharmaceuticals Inc shares had fallen by 15.2%
this
quarter and lost 48.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 15.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "buy."

Wall Street's median 12-month price target for Cyclacel
Pharmaceuticals Inc is $11.00 
This summary was machine generated from LSEG data August 15 at
04:27 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -1.43          -0.72          Beat
 Mar. 31 2024      -4.74          -2.27          Beat
 Dec. 31 2023      -5.89          -6.23          Missed
 Sep. 30 2023      -5.45          -7.35          Missed